Cargando…
Safety of live attenuated varicella-zoster vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study
BACKGROUND: In Japan, freeze-dried live attenuated varicella-zoster vaccine is available for adults aged ≥50 years to prevent herpes zoster. However, limited evidence has been accumulated regarding vaccine safety for patients with underlying illnesses, who have been considered as the high-risk group...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350288/ https://www.ncbi.nlm.nih.gov/pubmed/30691396 http://dx.doi.org/10.1186/s12879-019-3719-7 |
_version_ | 1783390421572911104 |
---|---|
author | Ohfuji, Satoko Ito, Kazuya Inoue, Megumi Ishibashi, Motoki Kumashiro, Hiroko Hirota, Yoshio Kayano, Eiji Ota, Naoshi |
author_facet | Ohfuji, Satoko Ito, Kazuya Inoue, Megumi Ishibashi, Motoki Kumashiro, Hiroko Hirota, Yoshio Kayano, Eiji Ota, Naoshi |
author_sort | Ohfuji, Satoko |
collection | PubMed |
description | BACKGROUND: In Japan, freeze-dried live attenuated varicella-zoster vaccine is available for adults aged ≥50 years to prevent herpes zoster. However, limited evidence has been accumulated regarding vaccine safety for patients with underlying illnesses, who have been considered as the high-risk group for herpes zoster. METHODS: A prospective cohort study of 1200 healthy adults and 300 patients with underlying illnesses such as malignancy, diabetes mellitus, autoimmune diseases, and renal diseases was conducted. All subjects were vaccinated and then their adverse events (AEs) were followed for 28 days after vaccination. Key safety measures included any AEs, severe AEs (SAEs), and vaccine-related AEs such as injection-site AEs and systemic AEs. The frequencies and 95% confidence intervals of AEs were calculated. RESULTS: During the follow-up period, 2 SAEs (bone fracture and acute cholecystitis) among healthy adults and 1 SAE (disseminated mycobacteriosis) among patients with underlying illnesses were reported, although none of them was diagnosed as vaccine-related. Vaccine-related AEs were reported in 42% of healthy adults and patients with underlying illnesses, and the proportions were similar between the groups. The most frequent AEs were injection-site AEs in both groups (i.e., 41 and 39%), and systemic AEs were observed in 4% of both groups. Only among healthy adults, those with a history of herpes zoster were more likely to report injection-site AEs than those without a history of herpes zoster (53% vs 39%). CONCLUSIONS: The present study confirmed the safety of freeze-dried, live attenuated varicella-zoster vaccine even in patients with underlying illnesses. A history of herpes zoster might be related to development of injection-site AEs in healthy adults. TRIAL REGISTRATION: The study was prospectively registered on Japic-Clinical Trials Information as JapicCTI-163415 on October 31, 2016. |
format | Online Article Text |
id | pubmed-6350288 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-63502882019-02-04 Safety of live attenuated varicella-zoster vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study Ohfuji, Satoko Ito, Kazuya Inoue, Megumi Ishibashi, Motoki Kumashiro, Hiroko Hirota, Yoshio Kayano, Eiji Ota, Naoshi BMC Infect Dis Research Article BACKGROUND: In Japan, freeze-dried live attenuated varicella-zoster vaccine is available for adults aged ≥50 years to prevent herpes zoster. However, limited evidence has been accumulated regarding vaccine safety for patients with underlying illnesses, who have been considered as the high-risk group for herpes zoster. METHODS: A prospective cohort study of 1200 healthy adults and 300 patients with underlying illnesses such as malignancy, diabetes mellitus, autoimmune diseases, and renal diseases was conducted. All subjects were vaccinated and then their adverse events (AEs) were followed for 28 days after vaccination. Key safety measures included any AEs, severe AEs (SAEs), and vaccine-related AEs such as injection-site AEs and systemic AEs. The frequencies and 95% confidence intervals of AEs were calculated. RESULTS: During the follow-up period, 2 SAEs (bone fracture and acute cholecystitis) among healthy adults and 1 SAE (disseminated mycobacteriosis) among patients with underlying illnesses were reported, although none of them was diagnosed as vaccine-related. Vaccine-related AEs were reported in 42% of healthy adults and patients with underlying illnesses, and the proportions were similar between the groups. The most frequent AEs were injection-site AEs in both groups (i.e., 41 and 39%), and systemic AEs were observed in 4% of both groups. Only among healthy adults, those with a history of herpes zoster were more likely to report injection-site AEs than those without a history of herpes zoster (53% vs 39%). CONCLUSIONS: The present study confirmed the safety of freeze-dried, live attenuated varicella-zoster vaccine even in patients with underlying illnesses. A history of herpes zoster might be related to development of injection-site AEs in healthy adults. TRIAL REGISTRATION: The study was prospectively registered on Japic-Clinical Trials Information as JapicCTI-163415 on October 31, 2016. BioMed Central 2019-01-28 /pmc/articles/PMC6350288/ /pubmed/30691396 http://dx.doi.org/10.1186/s12879-019-3719-7 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Ohfuji, Satoko Ito, Kazuya Inoue, Megumi Ishibashi, Motoki Kumashiro, Hiroko Hirota, Yoshio Kayano, Eiji Ota, Naoshi Safety of live attenuated varicella-zoster vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study |
title | Safety of live attenuated varicella-zoster vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study |
title_full | Safety of live attenuated varicella-zoster vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study |
title_fullStr | Safety of live attenuated varicella-zoster vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study |
title_full_unstemmed | Safety of live attenuated varicella-zoster vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study |
title_short | Safety of live attenuated varicella-zoster vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study |
title_sort | safety of live attenuated varicella-zoster vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350288/ https://www.ncbi.nlm.nih.gov/pubmed/30691396 http://dx.doi.org/10.1186/s12879-019-3719-7 |
work_keys_str_mv | AT ohfujisatoko safetyofliveattenuatedvaricellazostervaccineinpatientswithunderlyingillnessescomparedwithhealthyadultsaprospectivecohortstudy AT itokazuya safetyofliveattenuatedvaricellazostervaccineinpatientswithunderlyingillnessescomparedwithhealthyadultsaprospectivecohortstudy AT inouemegumi safetyofliveattenuatedvaricellazostervaccineinpatientswithunderlyingillnessescomparedwithhealthyadultsaprospectivecohortstudy AT ishibashimotoki safetyofliveattenuatedvaricellazostervaccineinpatientswithunderlyingillnessescomparedwithhealthyadultsaprospectivecohortstudy AT kumashirohiroko safetyofliveattenuatedvaricellazostervaccineinpatientswithunderlyingillnessescomparedwithhealthyadultsaprospectivecohortstudy AT hirotayoshio safetyofliveattenuatedvaricellazostervaccineinpatientswithunderlyingillnessescomparedwithhealthyadultsaprospectivecohortstudy AT kayanoeiji safetyofliveattenuatedvaricellazostervaccineinpatientswithunderlyingillnessescomparedwithhealthyadultsaprospectivecohortstudy AT otanaoshi safetyofliveattenuatedvaricellazostervaccineinpatientswithunderlyingillnessescomparedwithhealthyadultsaprospectivecohortstudy |